KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced that David W. Pritchard, president and chief executive officer, has decided to retire, effective immediately, and has also resigned his position as a member of the company’s Board of Directors. The company has named Herb C. Cross, chief financial officer, as interim CEO pending a search for a new chief executive officer… Read more
Shares of KaloBios Pharmaceuticals Inc opened today at $0.524 . KBIO has a 1-year high of $5.61 and a 1-year low of $0.47. The stock’s 50-day moving average is $1.76 and it’s 200-day moving average is $1.77.
KaloBios Pharmaceuticals is a biopharmaceutical company engaged in the development of monoclonal antibody therapeutics for diseases that burdens the society and to patients and their families.